Figure 2 The combination of BAG3 knockdown and olaparib treatment could suppress the proliferation of SKOV3 and A2780 cells and promote their apoptosis. (A) BrdU experiment showed that, compared with the NC group, BAG3 knockdown and olaparib treatment (4.0 µmol/L) inhibited the proliferation of cells, and BAG3 knockdown+olaparib treatment (4.0 µmol/L) had a more significant inhibitory effect. (B) Compared with the NC group, BAG3 knockdown and olaparib treatment (4.0 µmol/L) promoted OC cell apoptosis, and BAG3 knockdown+olaparib treatment (4.0 µmol/L) promoted cell apoptosis more significantly. (C) Western blot assay showed that, compared with the NC group, the expression of Bax protein increased and the expression of Bcl-2 decreased in the sh-BAG3 group and the olaparib (4.0 µmol/L) group. In the sh-BAG3+olaparib (4.0 µmol/L) group, the aforementioned effects were more significant. BAG3, Bcl-2-associated athanogene 3; BrdU, 5-Bromodeoxyuridine; ns, not significant; OC, ovarian cancer; sh-BAG3, BAG3 shRNA.